This was on the GSK board. Looks like a potential Brilinta all over again. Let's hope TPTB learned their lesson around $ and will be very competitive. Otherwise, DOA. Teva Pharmaceutical Industries Ltd. (TEVA) announces the approval of the generic equivalent to Lovaza® (Omega-3-Acid Ethyl Esters Capsules, USP), in the United States. Teva believes it is first-to-file and thus far is the only Company to receive an approval from FDA. Teva plans to commence shipping immediately. Lovaza® Capsules, marketed by GlaxoSmithKline, had annual sales of approximately $1.1 billion in the United States, according to IMS data as of December 2013.
Epanova is nothing more than a patent move for Crestor. The Teva drug will kill Epanova before it's born. Sorta like a Epa Abortion! Tooooo damn funny!
Certainly Epanova is a move towards a Crestor combination in the hopes of keeping the molecule going.
Managed market folks are having a hell of time getting coverage. God, all I see is another Brilinta w/o the data.
Yes, but AZ is saved by frenchie and we have soooooo many products ready to come to market-double digits! We need more reps for all there is to sell!
the cardiovascular effects are only part of the story. epanova also improves cognition. in the studies to date with statins there is a protective effect on alzheimers. http://www.alzheimersweekly.com/2013/09/the-bad-good-in-statins-alzheimers.html once the combo is available it will be prescribed mainly for the beneficial cns effects
You could take a generic statin and fish oil separately for a lot cheaper. Other Omega 3's also include DHA which anecdotally might improve cognition. You could also do this naturally by eating fish high in DHA, such as salmon, mackerel, herring, and sardines. A higher dose statin was listed as better than lower at improving cognition. It is doubtful prescribers are going to increase the dose of a statin if people don't need it, especially given other serious health risks relative to dosing. Too the combo would have to be approved for a cognitive indication for a rep to talk about it, but that hasn't seemed to deter AZ in the past.
